This month Rochester clinical stage biopharmaceutical company Vyriad is set to open the doors at their brand new 25,000 square foot facility. This custom build-out, constructed on leased space at the IBM Campus, will be the new Vyriad headquarters and manufacturing site. The facility is expected to increase the capacity of the company to produce and develop viral oncolytic cancer therapies and to potentially add new biotech jobs in Rochester.
Vyriad is developing viral therapies, based on Vesicular stomatitis virus (VSV) or measles platforms, to treat a variety of cancers. Spread and localization of Vyriad’s oncolytic therapies can be monitored non-invasively to ensure viral targeting to the cancer site. The company currently is running several Phase I and Phase II clinical trials to test the safety and efficacy of their viral therapies in patients.
Custom build-out of the Vyriad facility in northwest Rochester began this May, propelled by $9M of convertible debt financing. This funding included participation from Mayo Clinic, Rochester Area Economic Development, Inc., and the Southeast Minnesota Capital Fund.
The new facility includes two clean room suites where the viral manufacturing process is initiated and product is purified. Virus will be packaged and labeled in a separate room for compliance with new FDA regulations for Good Manufacturing Practice (GMP) investigational drugs. These rooms are also modular so they can be taken apart and re-organized as needed for future growth within the facility.
The buildout also includes an entire corridor dedicated to quality testing of both Vyriad’s end viral oncolytic products and of patient samples collected through sister company Imanis Life Sciences for sponsored clinical trials.
Vyriad’s leased space on the IBM Campus includes an additional 18,000 square feet for any future expansions of the biotech company at this location.
Design and buildout of the Vyriad facility was very intentional and forward thinking, with cleanliness being of utmost importance. The manufacturing, purification, packaging, and testing processes will all be uni-directional, with no backward flow of products or personnel within the isolated clean rooms to eliminate contamination. The rooms are additionally airlocked to restrict air and particle flow. Any breach or contamination in the system would shut down all production for about one month.
After an eight-month construction process, Vyriad will host an invitation only grand opening of its new manufacturing facility and headquarters on Wednesday January 30th. Buildout of the project was led by Benike Construction. RSP Architects served as lead design, with Madison-based Flad Architects crafting the Good Manufacturing Practice areas of the facility.
The new facility is expected to vastly increase the product run capacity of the company; currently Vyriad utilizes Mayo Clinic as a Contract Manufacturing Organization (CMO) for their viral therapies. The increased square footage also allows Vyriad to develop and create new viral products to add to their pipeline, increasing the capabilities of the company and allowing for potential expansion of their preclinical team.
Vyriad was founded by Mayo Clinic virologist Dr. Stephen Russell, Mayo Clinic oncologist Dr. Kah Whye Peng, and University of Miami cell biologist Dr. Glen Barber in 2012. Dr. Russell has served as CEO since 2016.
Learn more and follow the progress of this emerging local biopharmaceutical company on their website http://www.vyriad.com/.